In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines
出版年份 2022 全文链接
标题
In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 7, Pages 3724
出版商
MDPI AG
发表日期
2022-03-30
DOI
10.3390/ijms23073724
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer
- (2022) Maria Teresa Masucci et al. Cancers
- Papillary Thyroid Cancer Prognosis: An Evolving Field
- (2021) Salvatore Ulisse et al. Cancers
- Membrane type 1 matrix metalloproteinase regulates anaplastic thyroid carcinoma cell growth and invasion into the collagen matrix
- (2020) Tatsuya Yoshida et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase‐specific oncolytic Sendai virus
- (2019) Yoshihiro Miyagawa et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression
- (2019) Yuehua Ma et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Thyroid Imaging Reporting and Data System Score Combined with the New Italian Classification for Thyroid Cytology Improves the Clinical Management of Indeterminate Nodules
- (2017) Salvatore Ulisse et al. International Journal of Endocrinology
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
- (2016) Bryan R. Haugen et al. THYROID
- Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma
- (2015) Jesús Espinal-Enríquez et al. BMC GENOMICS
- Outcomes in Patients With Poorly Differentiated Thyroid Carcinoma
- (2014) T. Ibrahimpasic et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer
- (2014) Paul B. Romesser et al. JOURNAL OF SURGICAL ONCOLOGY
- Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer
- (2013) V Heinemann et al. BRITISH JOURNAL OF CANCER
- Urokinase Plasminogen Activator and Its Inhibitor Type-1 as Prognostic Factors in Differentiated Thyroid Carcinoma Patients
- (2013) Gordana Horvatic Herceg et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- In papillary thyroid carcinoma BRAFV600Eis associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval
- (2012) Salvatore Ulisse et al. CLINICAL ENDOCRINOLOGY
- FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma
- (2012) Roberto Bellelli et al. ENDOCRINE-RELATED CANCER
- Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells
- (2011) Theodore S. Nowicki et al. CELL CYCLE
- Molecular genetics and diagnosis of thyroid cancer
- (2011) Yuri E. Nikiforov et al. Nature Reviews Endocrinology
- High Expression of the Urokinase Plasminogen Activator and Its Cognate Receptor Associates with Advanced Stages and Reduced Disease-Free Interval in Papillary Thyroid Carcinoma
- (2010) Salvatore Ulisse et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells
- (2010) Theodore S. Nowicki et al. LARYNGOSCOPE
- The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
- (2009) Salvatore Ulisse et al. CURRENT CANCER DRUG TARGETS
- The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling
- (2009) Francesco Blasi et al. FEBS LETTERS
- Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies
- (2009) Daniel Buergy et al. INTERNATIONAL JOURNAL OF CANCER
- A Small-Molecule Triptolide Suppresses Angiogenesis and Invasion of Human Anaplastic Thyroid Carcinoma Cells via Down-Regulation of the Nuclear Factor- B Pathway
- (2009) W. Zhu et al. MOLECULAR PHARMACOLOGY
- Increasing incidence of thyroid cancer is due to increased pathologic detection
- (2008) Simon Grodski et al. SURGERY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started